Skip to main content

Table 3 Predictors of survival in patients treated with chemotherapy

From: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

  Complete-case analysis (n = 44) Multiple imputation by chained equation (n = 50)
Unadjusted HR Adjusted HR Unadjusted HR Adjusted HR
Estimate 95% CI P Estimate 95% CI P Estimate 95% CI P Estimate 95% CI P
Sex
 Male (Reference) 1.000    1.000   
 Female 0.537 0.255 — 1.131 0.102 0.606 0.303 — 1.213 0.157
Age, y
  < 65 (Reference) 1.000   1.000   1.000   1.000  
  ≥ 65 1.982 0.981 — 4.004 0.057 3.404 1.472 — 7.875 0.004 1.877 0.981 — 3.591 0.057 2.242 1.119 — 4.494 0.023
ECOG PS
 0 (Reference) 1.000   1.000   1.000   1.000  
  ≥ 1 1.384 0.626 — 3.060 0.422 1.709 0.752 — 3.885 0.201 1.292 0.638 — 2.619 0.477 1.293 0.627 — 2.667 0.486
Prior surgical resection
 No (Reference) 1.000    1.000   
 Yes 0.798 0.414 — 1.537 0.500 0.760 0.413 — 1.397 0.377
Tumor location
 Head (Reference) 1.000     1.000    
 Body-Tail 1.124 0.574 — 2.200 0.733 1.153 0.619 — 2.145 0.654
Extent of disease
 Locally advanced (Reference) 1.000   1.000   1.000   1.000  
 Metastatic 0.820 0.316 — 2.132 0.685 0.630 0.210 — 1.891 0.410 0.820 0.319 — 2.107 0.681 0.606 0.204 — 1.805 0.369
Location of metastases
 Liver 2.173 1.111 — 4.248 0.023 2.373 1.086 — 5.184 0.030 1.919 1.034 — 3.559 0.039 1.721 0.856 — 3.457 0.127
 Lymph node 0.805 0.413 — 1.570 0.525   0.831 0.442 — 1.563 0.566  
 Peritoneal 0.865 0.406 — 1.842 0.707 0.933 0.458 — 1.901 0.849
LDH, U/L
  ≤ 250 (Reference) 1.000    1.000   
  > 250 0.715 0.324 — 1.576 0.405 0.829 0.407 — 1.686 0.604
CRP, mg/L
  ≤ 10 (Reference) 1.000    1.000   
  > 10 1.624 0.846 — 3.116 0.145 1.650 0.898 — 3.031 0.106
CEA, ng/mL
  ≤ 5.0 (Reference) 1.000    1.000   
  > 5.0 1.239 0.600 — 2.559 0.562 1.337 0.675 — 2.650 0.405
CA19–9, U/mL
  ≤ 37.0 (Reference) 1.000    1.000   
  > 37.0 1.032 0.537 — 1.981 0.926 1.143 0.620 — 2.107 0.669
Histological subtype
 UC without OGCs (Reference) 1.000   1.000   1.000   1.000  
 UC with OGCs 0.935 0.385 — 2.268 0.882 2.372 0.848 — 6.635 0.100 0.857 0.378 — 1.943 0.713 0.826 0.354 — 1.930 0.660
Use of paclitaxel-containing regimen in any line
 No (Reference) 1.000   1.000   1.000   1.000  
 Yes 0.216 0.076 — 0.620 0.004 0.181 0.062 — 0.534 0.002 0.218 0.077 — 0.621 0.004 0.221 0.076 — 0.647 0.006
  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, UC undifferentiated carcinoma, OGCs osteoclast-like giant cells